Pegfilgrastim biosimilar - Coherus BioSciences

Drug Profile

Pegfilgrastim biosimilar - Coherus BioSciences

Alternative Names: CHS-1701

Latest Information Update: 08 Jul 2017

Price : $50

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Neutropenia

Most Recent Events

  • 12 Jun 2017 Coherus BioSciences receives complete response letter from the FDA for pegfilgrastim biosimilar in IgA nephropathy
  • 02 Jun 2017 Pharmacodynamics, pharmacokinetic and adverse events data from a phase I trial in Healthy volunteers presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 25 Apr 2017 Coherus BioSciences completes initial phases of patent exchange procedure with Amgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top